| Literature DB >> 329910 |
.
Abstract
In a phase II trial, prednimustine was often efficient in treating chronic lymphoid leukaemia (CLL) patients and was also active in some patients with lymphosarcoma, melanoma and bronchus carcinoma. Tolerance was generally excellent, the most critical side effect being thrombocytopenia in the case of CLL.Entities:
Mesh：
Substances：
Year: 1977 PMID： 329910
Source DB: PubMed Journal: Biomedicine ISSN： 0300-0893